Several preclinical and clinical studies investigated GBM treatment, where the specific antigenic targets of CAR-T cells were interleukin-13 receptor alpha 2 (IL-13Rα2), human epidermal growth factor receptor 2 (HER2), erythropoietin-producing hepatocellular carcinoma A2 (EphA2) receptor, and epidermal growth factor receptor variant III (EGFRvIII) [45,46,47,48]. Here, IL13RA2 is linked to hepatocellular carcinoma.